NCT02293850 - Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2021

Conditions

Carcinoma, Hepatocellular

Interventions

BIOLOGICAL

OBP-301

A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.

Trial Locations (2)

10002

RECRUITING

National Taiwan University Hospital, Taipei

602-739

RECRUITING

Pusan National University Hospital, Busan